S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
All the trading advice you’ve ever received boils down to this (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
All the trading advice you’ve ever received boils down to this (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
All the trading advice you’ve ever received boils down to this (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
All the trading advice you’ve ever received boils down to this (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
All the trading advice you’ve ever received boils down to this (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
All the trading advice you’ve ever received boils down to this (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
The Dodgers gave Shohei Ohtani $700 million to hit and pitch — but also because he can sell
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Elon Musk restores X account of conspiracy theorist Alex Jones
Freshworks gets juiced on its AI customer engagement platform
All the trading advice you’ve ever received boils down to this (Ad)
At UN climate talks, cameras are everywhere. Many belong to Emirati company with a murky history
The EU wants to put a tax on emissions from imports. It's irked some other nations at COP28
All the trading advice you’ve ever received boils down to this (Ad)
Miyazaki's 'The Boy and the Heron' is No. 1 at the box office, a first for the Japanese anime master
Much of Kenya falls into darkness in the third nationwide power blackout in 3 months

Connect Biopharma (CNTB) Stock Forecast & Price Target

$0.92
-0.01 (-1.08%)
(As of 12/8/2023 08:56 PM ET)
Compare
Today's Range
$0.90
$0.93
50-Day Range
$0.79
$2.06
52-Week Range
$0.53
$2.84
Volume
81,400 shs
Average Volume
244,667 shs
Market Capitalization
$50.67 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.00

Connect Biopharma Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 2 Analyst Ratings

Analysts' Consensus Price Target

$6.00
552.17% Upside
High Forecast$7.00
Average Forecast$6.00
Low Forecast$5.00
TypeCurrent Forecast
12/11/22 to 12/11/23
1 Month Ago
11/11/22 to 11/11/23
3 Months Ago
9/12/22 to 9/12/23
1 Year Ago
12/11/21 to 12/11/22
Consensus Rating
Buy
Buy
Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
2 Buy rating(s)
2 Buy rating(s)
1 Buy rating(s)
2 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$6.00$6.00$7.00$23.50
Predicted Upside552.17% Upside569.10% Upside488.24% Upside558.26% Upside
Get Connect Biopharma Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter.


CNTB Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

CNTB Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Connect Biopharma Stock vs. The Competition

TypeConnect BiopharmaMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.67
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside552.17% Upside737.73% Upside3,819.11% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
9/13/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$5.00+566.57%
4/12/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
T. Smith
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 03:38 AM ET.












CNTB Price Target - Frequently Asked Questions

What is Connect Biopharma's consensus rating and price target?

According to the issued ratings of 2 analysts in the last year, the consensus rating for Connect Biopharma stock is Buy based on the current 2 buy ratings for CNTB. The average twelve-month price prediction for Connect Biopharma is $6.00 with a high price target of $7.00 and a low price target of $5.00. Learn more on CNTB's analyst rating history.

Do Wall Street analysts like Connect Biopharma more than its competitors?

Analysts like Connect Biopharma more than other Medical companies. The consensus rating for Connect Biopharma is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how CNTB compares to other companies.

Does Connect Biopharma's stock price have much upside?

According to analysts, Connect Biopharma's stock has a predicted upside of 569.10% based on their 12-month stock forecasts.

What analysts cover Connect Biopharma?

Connect Biopharma has been rated by Cantor Fitzgerald in the past 90 days.


Stock Ratings Reports and Tools

This page (NASDAQ:CNTB) was last updated on 12/11/2023 by MarketBeat.com Staff

My Account -